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Abstract. Hereditary NonPolyposis Colorectal Cancer (Lynch syndrome) is an autosomal dominant disease caused by germline
mutations in a class of genes deputed to maintain genomic integrity during cell replication, mutations result in a generalized
genomic instability, particularly evident at microsatellite loci (Microsatellite Instability, MSI). MSI is present in 85–90% of
colorectal cancers that occur in Lynch Syndrome. To standardize the molecular diagnosis of MSI, a panel of 5 microsatellite
markers was proposed (known as the “Bethesda panel”). Aim of our study is to evaluate if MSI testing with two mononucleotide
markers, such as BAT25 and BAT26, was sufficient to identify patients with hMLH1/hMSH2 germline mutations. We tested 105
tumours for MSI using both the Bethesda markers and the two mononucleotide markers BAT25 and BAT26. Moreover, immuno-
histochemical evaluation of MLH1 and MSH2 proteins was executed on the tumours with at least one unstable microsatellite,
whereas germline hMLH1/hMSH2 mutations were searched for all cases showing two or more unstable microsatellites.
The Bethesda panel detected more MSI(+) tumors than the mononucleotide panel (49.5% and 28.6%, respectively). However,
the mononucleotide panel was more efficient to detect MSI(+) tumours with lack of expression of Mismatch Repair proteins
(93% vs 54%). Germline mutations were detected in almost all patients whose tumours showed MSI and no expression of
MLH1/MSH2 proteins. No germline mutations were found in patients with MSI(+) tumour defined only through dinucleotide
markers. In conclusion, the proposed mononucleotide markers panel seems to have a higher predictive value to identify hMLH1
and hMSH2 mutation-positive patients with Lynch syndrome. Moreover, this panel showed increased specificity, thus improving
the cost/effectiveness ratio of the biomolecular analyses.
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1. Introduction
Hereditary Non-Polyposis Colorectal Cancer (HN-
PCC) is a common autosomal dominant disease asso-
ciated with an increased lifetime risk for cancer, espe-
cially colorectal and endometrial carcinomas [1] HN-
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PCC accounts for approximately 2–5% of all colorectal
tumours and is characterized by an early age of can-
cer onset and by the frequent development of multi-
ple tumours. This familial cancer syndrome is caused
by germline mutations in genes encoding components
of the post-replication DNA Mismatch Repair system
(DNA MMR system) [2]. DNA MMR system is re-
quired for correction of mismatches that occur during
replication, and is composed by at least five genes:
hMLH1, hMSH2, hMSH6, hMSH3, hPMS2 [3,4]. In
the majority of families with HNPCC, germline muta-
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tions affect hMLH1 or hMSH2 [5], though mutation
have also been reported in hMSH6 and hPMS2 gene [6].
Inactivation of MMR genes results in a high frequency
of small deletions or insertions with simple repeat se-
quences that occur ubiquitously throughout the genome
(microsatellites) and is referred to as Microsatellite In-
stability (MSI).
A total 85–90% of HNPCC patients show MSI(+) tu-
mours, whereas MSI is present in only 10–15% of spo-
radic colorectal tumours [7]. Since HNPCC-associated
colorectal malignancies are characterized by MSI, to
test a tumour for microsatellite instability is an im-
portant tool to identify these families. To standardize
the molecular definition of MSI, in December 1997 a
National Cancer Institute Workshop on HNPCC rec-
ommended a panel of five microsatellite markers; the
panel included two mononucleotide repeats (BAT25
and BAT26) and three dinucleotide repeats (D2S123,
D5S346 and D17S250). Using this panel, usually re-
ferred to as the “Bethesda panel” high-frequency Mi-
crosatellite Instability (MSI-H) was defined as hav-
ing instability in two or more markers, whereas low-
frequency (MSI-L) and microsatellite stable (MSS)
were defined as having instability in one or zero mark-
ers, respectively. The 2002 Consensus meeting recog-
nized that dinucleotide markers were less sensitive than
mononucleotide to identify MSI-H tumours and that
mononucleotide repeats should replace dinucleotide in
the panel [8]. The use of mononucleotide repeats such
as BAT25 (an intronic T25 sequence in the c-KIT gene)
and BAT26 (an intronic A26 sequence in the hMSH2
gene) has proven to be very useful for the identification
of the MSI-H group of tumours [9]. Instability at these
loci appears in the majority of neoplasms defined as
MSI-H, but rarely in MSI-L tumours [10]. Therefore,
the exclusive use of mononucleotide repeats seems suf-
ficient to detect true MSI [11]. It is noteworthy that
hMLH1 and hMSH2 germline mutations give rise to
“typical” HNPCC families that fulfil the so called “Am-
sterdam criteria”, and show a high degree of MSI in the
tumours [12]. In addition, recent studies have shown
that MSI can be an important prognostic marker, since
MSI-H colorectal cancers are often associated with a
more favourable prognosis after surgical resection [13,
14]. Moreover, there is evidence suggesting that col-
orectal cancer patients with MSI-H tumours might re-
spond differently to 5FU-based chemotherapy. Thus
the assessment of the MSI status in colorectal cancer
can be of relevance for at least three purposes: first, as
a screening tool for HNPCC; second, as a prognostic
marker; and finally, as a potential predictive factor of
response to chemotherapy.
The accuracy of MSI as a marker to identify colon
cancer that has lost MMR function is depending on
the technical details of the assay and, in particular, on
the type of markers used to detect MSI. The aim of
the study was to evaluate the specificity and sensitiv-
ity of a mononucleotide marker panel, composed by
BAT25 and BAT26, in order to identify hMLH1 and
hMSH2 mutation-positive HNPCC patients. For these
purposes, we compared the proposed panel with the
classical “Bethesda panel” in a series of 105 colorec-
tal neoplasms from HNPCC or “Suspected HNPCC”
families.
2. Patients and methods
2.1. Patients
The patients described in this study were recruited
through the specialized colorectal cancer Registry of
the Health Care District 16, instituted in 1984, which
included the town of Modena (Northern Italy) and 10
surrounding communities. We identified HNPCC pa-
tients following a previously described multistep ap-
proach [15]. Briefly, the nuclear pedigrees of all in-
cident cases of colorectal cancer diagnosed during the
period 1984–2003 were collected and stratified accord-
ing to the presence of some clinical features, all in-
dicative of an increased risk of HNPCC (such as “ver-
ticality”, aggregation of cancer in a given sibship, ear-
ly age of cancer onset, presence of multiple primaries,
localization in the right colon and mucinous histolog-
ical type). When a patient had 2 or more of these
features, an extended genealogic tree was traced and
then analyzed for the presence of diagnostic criteria
for HNPCC (Amsterdam criteria II) [16]. All together
we could identify 36 HNPCC kindreds and 75 families
which fulfilled the clinical criteria of suspected HN-
PCC suggested by Park and coworkers [17]. According
to these authors, suspected HNPCC is defined as a kin-
dred with a) at least two HNPCC-associated cancers in
first-degree relatives (colorectum, endometrium, small
intestine, urinary tract), b) multiple colorectal tumours,
or at least one HNPCC-associated cancer diagnosed
before the age of 50 years, or development of tumours
of the Lynch spectrum among family members. A total
of 105 eligible and unrelated probands with colorectal
cancer were recruited in this study, 33 of whom were
from HNPCC families whereas the remaining 72 were
from suspected HNPCC.
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2.2. Microdissection and DNA extraction
Formalin-fixed, paraffin-embedded normal and tu-
mour tissues were taken from all patients investigated.
At least one tissue block representative of the tumour
and one separate block containing normal colonic mu-
cosa could be obtained. Serial sections from paraffin-
embedded matched normal and neoplastic primary
tissue (5 µm) were stained with Hematoxylin-eosin
(H&E); representative normal and tumour regions were
identified by microscopic examination. Area of tu-
mour tissue with more than 80% of malignant cells
were selected in all cases. Ten of these selected ar-
eas were manually scraped off using a surgical scalpel
under stereomicroscopic guidance and placed into mi-
crocentrifuge tubes. Xilene was added to each tube
to dissolve paraffin. The resulting samples were then
incubated overnight at 50◦ in a Tween 20-proteinase K
lysis buffer. After digestion the DNA was purified with
a NaCl-saturated solution and precipitated in absolute
ethanol. Before using a template DNA for PCR analy-
sis, heat inactivation of proteinase K was carried out at
80◦ for 10 minutes.
2.3. MSI analysis
The MSI status of 105 tumours was evaluated us-
ing the full basic set of five markers (BAT25, BAT26,
D2S123, D5S346, D17S250) and was defined accord-
ing to the Bethesda guideline. It is noteworthy that the
panel includes also the two mononucleotide markers
BAT25 and BAT26. Using the mononucleotide markers
panel, a tumour was defined as MSI(+) when showed
instability with both markers and MSI(-) when showed
no instability. DNA from normal and tumour tissue
was amplified in a 10 µl volume containing 30-50 ng
of DNA, 0.15 pmol of dye-labelled forward and un-
labeled reverse primers, 2 mM concentration of each
deoxynucleotide triphosphate, 1.5 mM MgCl2, 50 mM
KCl, 10 mM Tris (pH 8.3) and 0.6 units of Taq poly-
merase. Thermocycling conditions were: 94◦C, 4 min,
followed by 11 touchdown cycles, each with a denatur-
ing step at 94◦C for 30 s, an extension step at 72◦C for
15 s and a 75 s annealing step that decreased 1◦C/cycle
(beginning at 65◦C in the first cycle and decreasing to
55◦C in the eleventh cycle). The eleventh cycle was
then repeated 26 times for a total of 37 cycles of PCR;
finally an extension step of 4 min at 72◦C followed by
storage at 4◦C. PCR products were prepared for anal-
ysis by pooling 2 µl of dye-D2 reaction, 1 µl of dye-
D3 and 0.5 µl of dye-D4 reaction; 40 µl of deionized
formamide and 0.5 µl of CEQ DNA size standard-400
were added to 0.7 µl of the each mixture. All samples
were run on CEQ 8000 sequencer and analyzed us-
ing CEQ 8000 Fragment Analysis System by Beckman
Coulter.
2.4. Immunohistochemical analysis
Immunohistochemical evaluation (IHC) of MSH2
and MLH1 protein expression was carried out on
paraffin-embedded tissue sections of all tumours with
at least one unstable microsatellite. MSI-L tumours
were also analyzed for the expression of MSH6 protein.
Slides with 5 µm sections containing tumour tissue and
normal colonic mucosa were deparaffinized in xilene
and rehydrated in graded alcohols. Endogenous perox-
idase was blocked by 3% hydrogen peroxide and anti-
gen was revealed with 10 mM citrate buffer (pH 6.0) at
350 W for 30 min, by microwave. Mouse monoclon-
al antibodies to full-length MLH1 and MSH2 (clone
G168-15, G129-1129, PharMingen, San Diego, CA)
were used at a 1:100 dilution, while mouse monoclon-
al antibody against MSH6 protein (clone 44 Transduc-
tion Italia) at a 1:2000 dilution, overnight. Immunos-
taining was executed by the avidin-biotin peroxidase
technique; diaminobenzidinewas used as a chromogen.
Slides were counterstained with hematoxylin. Normal
tissue and stromal cells or lymphocytes adjacent to the
respective tumour were used as internal positive con-
trols. Loss of MLH1 and MSH2 protein expression
was defined as complete absence of nuclear staining in
tumour cells (but maintained in normal epithelial and
stromal cells).
2.5. Analysis of germline mutations in hMLH1 and
hMSH2
In all patients whose tumours were MSI(+) and
with no MLH1/MSH2 protein expression, a search for
germline mutations of the main MMR genes was car-
ried out by direct genomic sequencing of all exons.
Sequencing was executed on the basis of the immuno-
histochemical results. All patients with MSI-H tu-
mours and no MLH1 protein expression in the tumours
had previously been evaluated for a Northern Italian
founder mutation of the hMLH1 gene described of by
our group [18]. Molecular analysis of both hMLH1
and hMSH2 genes was extended also to MSI(+) cas-
es that had normal expression of the main MMR pro-
teins. Amplification products were generated with
primers located in the flanking introns approximately
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Table 1
MSI analysis in the 105 colorectal tumours according to two different marker panels and expression of
MLH1-MSH2 protein in MSI(+) tumours
MSI(+) MSI(−) no expression expression total MSI(+)
Bethesda Panel 52 (49.5%) 39 (37.14%)∗ 28 (54%) 24 (46%)§ 52
Mononucleotide panel 30 (28.6%) 75 (71.4%)∗ 28 (93%) 2 (75%)§ 30
∗χ2 = 16.35; p < 0.001.
§F1 = 13.70; p < 0.001.
Table 2
MSI(+) tumours detected with the mononucleotide panel, expression of MMR protein and germline mutations
Tumour Clinical features MSI(+)with MLH1protein MSH2 protein Germline mutation
mononucleotide panel expression expression
BAT25 BAT26
7 HNPCC + + − + +
15 HNPCC + + − + +
18 S-HNPCC + + + − nv
19 S-HNPCC + + − + nv
20 S-HNPCC + + − + nv
21 S-HNPCC + + − + nv
25 S-HNPCC + + − + +
26 HNPCC + + + + +
29 HNPCC + + + − +
32 Muir-Torre + + + − +
38 HNPCC + + − + +
40 HNPCC + + + − +
41 HNPCC + + + + +
43 Muir-Torre + + + − +
48 HNPCC + + + − +
56 HNPCC + + − + nv
58 HNPCC + + − + +
68 HNPCC + + − + +
71 HNPCC + + − + +
73 HNPCC + + − + +
77 HNPCC + + − + +
79 HNPCC + + + − +
80 S-HNPCC + + + − +
81 HNPCC + + + − +
84 S-HNPCC + + + − +
88 HNPCC + + + − +
89 HNPCC + + − + +
93 HNPCC + + − + +
98 HNPCC + + − + +
103 HNPCC + + − + +
not valued = nv, Suspected HNPCC = S-HNPCC.
50 base pair from the respective intron/exon borders
to detect all possible splice junction mutations. Direct
sequencing of the PCR products was obtained using
Dye Terminator Cycle Sequencing Kit (CEQ DTCS
Kit, Beckman Coulter) and reactions were run on an
CEQ 8000 capillary sequencer (Beckman Coulter) ac-
cording to the manufacturer’s instructions. To exclude
the possibility of large genomic deletions of hMLH1
and hMSH2, all patients with MSI-H were analyzed
by Multiplex Ligation-dependent Probe Amplification
(MLPA). The MLPA test for hMLH1 and hMSH2 was
obtained from MCR-Holland, Amsterdam, the Nether-
lands. Pathogenic mutations were detected twice and
confirmed in a second blood sample of the patient. The
purpose of the study was clearly explained and an in-
formed consent was obtained.
2.6. Statistics
Pearson’s χ2 or Fisher’s exact tests were applied to
the results as appropriate. All values of p  0.05 were
considered significant. Sensitivity and specificity for
MSI markers and immunohistochemistry were defined
using the germline mutations results as the gold stan-
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Table 3
MSI(+) tumours detected with the Bethesda panel, expression of MLH1/MSH2 protein and germline mutations
Tumour Clinical feature MSI(+) with Bethesda dinucleotide panel MLH1 protein MSH2 protein Germline mutation
expression expression
5 S-HNPCC D5S346-D17S250 + + −
7 HNPCC BAT25-BAT26 − + +
8 S-HNPCC D5S346-D17S250 + + −
10 HNPCC D5S346-D17S250-D2S123 + + −
15 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
17 HNPCC D5S346-D17S250 + + −
18 S-HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 + − nv
19 S-HNPCC BAT25-BAT26-D5S346-D2S123 − + nv
20 S-HNPCC BAT25-BAT26-D17S250 − + nv
21 S-HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + nv
22 S-HNPCC D5S346-D17S250-D2S123 + + −
24 S-HNPCC D5S346-D17S250 + + −
25 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
26 HNPCC BAT25-BAT26-D5S346-D2S123 + + +
28 HNPCC D5S346-D17S250-D2S123 + + −
29 HNPCC BAT25-BAT26 + − +
32 Muir-Torre BAT25-BAT26-D5S346-D17S250-D2S123 + − +
37 HNPCC D5S346-D2S123 + + −
38 HNPCC BAT25-BAT26-D5S346 − + +
40 HNPCC BAT25-BAT26-D17S250-D2S123 + − +
41 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 + + +
43 Muir-Torre BAT25-BAT26-D5S346-D17S250-D2S123 + − +
44 S-HNPCC D5S346-D17S250 + + −
46 S-HNPCC D5S346-D17S250 + + −
48 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 + − +
49 S-HNPCC D5S346-D2S123 + + −
56 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 + − nv
57 S-HNPCC D17S250-D2S123 + + −
58 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
61 S-HNPCC D5S346-D17S250 + + −
62 S-HNPCC D5S346-D17S250-DS123 + + −
64 HNPCC D17S250-D2S123 + + −
68 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
71 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
72 S-HNPCC D5S346-D17S250 + + −
73 HNPCC BAT25-BAT26-D5S346 − + +
77 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 + − +
79 HNPCC BAT25-BAT26-D5S346-D2S123 + − +
80 S-HNPCC BAT25-BAT26-D17S250-D2S123 + − +
81 HNPCC BAT25-BAT26-D17S250 + − +
84 S-HNPCC BAT25-BAT26-D5S346-D2S123 + − +
85 S-HNPCC D17S250-D2S123 + + −
87 S-HNPCC D17S250-D2S123 + + −
88 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 + − +
89 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
91 HNPCC D5S346-D17S250 + + −
93 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
96 HNPCC D5S346-D17S250 + + −
98 HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
99 S-HNPCC D17S250-D2S123 + + −
103 S-HNPCC BAT25-BAT26-D5S346-D17S250-D2S123 − + +
104 S-HNPCC D5S346-D17S250 + + −
not evaluated = nv, Suspected HNPCC = S-HNPCC.
dard. Specificity was defined as percentage of subjects
without mutation who have a negative test result and
sensitivity as percentage of subjects with mutation who
have a positive test result. The “tests” were MSI anal-
ysis with Bethesda or mononucleotide panel, immuno-
histochemical analysis and single mono/dinucleotide
markers. Statistical analysis was carried out using the
SPSS 10.0 statistical software (SPSS, Chicago, IL).
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Table 4
Specificity and sensitivity of MSI and IHC in predicting the presence
of germline mutations in HNPCC or suspected HNPCC families
Specificity (%) Sensitivity (%)
Bethesda markers panel 70.7 (53/75) 100 (25/25)
Mononucleotide markers panel 100 (75/75) 100 (25/25)
Immunohistochemical analysis 100 (75/75) 92.0 (23/25)
BAT25 marker 100 (75/75) 100 (25/25)
BAT26 marker 100 (75/75) 100 (25/25)
D2S123 marker 81.3 (61/75) 80.0 (20/25)
D5S346 marker 72.0 (54/75) 80.0 (20/25)
D17S250 marker 64.0 (48/75) 72.0 (18/25)
3. Results
The 105 primary colorectal carcinomas were evalu-
ated for MSI status by using both the Bethesda marker
panel and the alternative mononucleotide panel. The
results are summarized in Table 1. With the Bethes-
da panel, 52 tumours (49.5%) were found to be pos-
itive for two or more markers (high MSI or MSI-H).
Using the alternative mononucleotide panel, 30 out of
105 (28.6%) tumours could be classified as MSI(+)
(p < 0.001). Moreover, with the Bethesda panel 14
tumours (13.4%) could be scored as MSI-L, whereas
no tumour appeared unstable at only 1 marker with the
mononucleotide panel. Out of the 52 MSI(+) tumours
detected with the Bethesda panel, 28 (54%) showed
lack of expression in one of the two main MMR pro-
teins (MLH1 or MSH2). In contrast, 28 of 30 MSI(+)
tumours detected by the alternative mononucleotide
markers (93%) showed lack of expression of MSH2 or
MLH1. Thus, mononucleotide markers were signifi-
cantly more efficient (F1 = 13.70 p < 0.001) in detect-
ing MSI(+) tumours associated with lack of expres-
sion of MMR proteins. Moreover, protein expression
(MLH1/MSH2/MSH6) was normal in the 14 tumours
defined as MSI-L (with the Bethesda markers). Thus,
the results suggest that the Bethesda panel is probably
preferable for detecting all tumours with microsatel-
lite instability (including those with MSI-L), whereas
mononucleotide markers instability seems more close-
ly associated with lack of expression of the MMR pro-
teins.
Tables 2 and 3 show the relationship between insta-
bility, lack of expression of MSH2/MLH1 proteins and
constitutional mutations. With mononucleotide mark-
ers, germline mutations were found in all cases with
MSI(+) tumours and lack of expression in one of the
MMR proteins (with two exceptions, in which both the
main proteins were normally expressed). In contrast,
in almost half of the cases assessed with the Bethesda
panel, microsatellite instability was not associated with
lack of expression of MMR proteins or constitutional
mutations. Thus, the Bethesda and the mononucleotide
panel showed similar sensitivity in predicting the pres-
ence of germline MMR gene defects (25 of 25, 100%),
but a different specificity, which was much higher for
the mononucleotide panel (Table 4).
Germline mutations in either hMLH1 or hMSH2
genes could be analyzed in 47 of 52 patients with
MSI(+) tumours. Three out of the 5 remaining pa-
tients showed no expression of both MLH1 and MSH6
proteins and hypermethylation of the MLH1 promot-
er region. Constitutional defects were detected in 25
patients from 20 different families; mutations in the
hMSH2 gene were found in 11 of them, while in the re-
maining 9 families MLH1 gene mutations were detect-
ed. Clinical features (HNPCC, suspected HNPCC or
Muir-Torre syndrome), MSI, immunohistochemistry,
molecular changes and their consequence are illustrat-
ed in Table 5. One of these molecular changes (ins T at
2269) was found in the constitutional DNA of 4 appar-
ently unrelated large families living in the area of Mod-
ena and Reggio Emilia, Northern Italy. This finding has
been interpreted as a “Founder” effect [18]. Rather in-
terestingly, no germline mutations could be detected in
patients with MSI-H tumours defined only through din-
ucleotide instability (i.e., with stable mononucleotide).
This last observations further emphasizes the role and
significance of mononucleotide markers in detecting
HNPCC (or constitutional mutations in the main MMR
genes).
4. Discussion
The main objective of this study was to develop a
simple, rapid and more accurate method of MSI assess-
ment for the identification of HNPCC families. For this
reason, we evaluated the efficacy of the Bethesda mark-
ers versus a mononucleotide marker panel, composed
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by BAT25 and BAT26, in detecting hMLH1/hMSH2
germline mutations.
The results of our study showed that mononucleotide
markers are more specific to identify hMLH1/hMSH2
mutation carriers than the Bethesda panel (100% versus
70.7%, respectively). Main limitations of the Bethesda
panel are the result of including dinucleotide repeats,
since these are less sensitive and less specific for the
identification of tumours with no expression of MMR
protein and no germline mutation in hMSH1/hMSH2
gene, as compared with mononucleotide repeats. Al-
though using the Bethesda markers a tumour with in-
stability at two loci is considered MSI-H, this is not
necessarily true if the instability is detected only with
dinucleotides. There is evidence [19] suggesting that
when enough dinucleotide markers are tested almost all
colorectal tumours will show some degree of instabili-
ty. In our study, we found 22 MSI-H tumours at dinu-
cleotide loci with normal expression of MLH1/MSH2
proteins and with no germline mutation detectable in
the patients. False positive results with the MSI as-
say, besides an increased time and costs for the IHC
test, may lead to over-treatment and unnecessary psy-
chologic stress for the patients. In contrast, the use of
mononucleotide markers -such as BAT25 and BAT26-
allows accurate evaluation of tumours with MMR defi-
ciency without being hindered by the MSI-L category,
whose real existence has yet to be proven, and that does
not seem to be a homogeneous group [20]. Therefore,
it is tempting to delete this category of tumours, which
seem to show clinical features in common with MSS
tumours and that are different from the MSI-H sta-
tus of tumours from HNPCC patients. More recently,
Vasen et al. suggested that among tumours with MSI-
L, those with instability at dinucleotide loci showed
more often normal expression of MMR protein than
MSI-L tumours with instability at a mononucleotide
locus [21]. In our study we detected 14 MSI-L tumours
where the single unstable repeat was a dinucleotide, and
MLH1/MSH2/MSH6 proteins were always normally
expressed. Moreover, some MSI tumours with MMR
deficiency caused by hMSH6 mutations did not show
alterations at dinucleotide repeats [22]. It is important
to consider that the MSH6 protein is not involved in the
mismatch repair of two or more base pairs, so that the
analysis with dinucleotide markers may not recognize
many tumours [23]. Thus, we suggest that the use of
mononucleotide markers – such as BAT25 and BAT26
could be particularly useful to identify tumours with
germline mutations of hMSH6.
In recent years several authors underlined the ad-
vantages of IHC over MSI testing [24–26]. IHC was
reported to have high sensitivity, to be less expensive
and more rapid than MSI testing. Moreover, the loss
of one of the MMR proteins indicates which gene is
likely to be involved in the disease. Our results demon-
strate that IHC with the two commonly used mono-
clonal antibodies against MLH1 and MSH2 proteins
detected a significant fraction of tumours (23 of 25) re-
sected from germline mutation carriers. The sensitivi-
ty and specificity of IHC in predicting hMLH1/hMSH2
germline mutations was 92% and 100%, respectively,
whereas MSI testing showed 100% in both sensitivity
and specificity. Thus, we suggest that IHC can be used
as an additional screening procedure in order to identi-
fy patients with MMR germline mutations. However,
the existence of a small number of cases harbouring
a disease-causing mutation, exhibiting MSI(+) pheno-
type, and showing normal expression of MMR protein
indicates that IHC can hardly replace MSI testing. For
this reason, we prefer MSI analysis as the initial step in
clinically selected families. In MSI(+) tumours, IHC
should be carried out as a second step and, if a nega-
tive staining pattern is found, mutation analysis of the
involved gene should be the final step.
In conclusion, MSI testing is becoming more and
more popular than in the past and it is likely that this
assay will be of routine in many laboratories. If we are
interested in detecting the MSI status in general, for
example because MSI(+) tumours seem to have a more
favourable clinical outcome [27], and could be treat-
ed differently from MSS tumours, then the Bethesda
markers are probably those of choice.However, if a re-
searcher is interested in looking for HNPCC among pa-
tients with apparently sporadic colorectal cancer (i.e.,
the molecular screening frequently advocated by de la
Chapelle and collaborators) [28], then the highly more
sensitive (in identifying HNPCC) and specific mononu-
cleotide markers – as those proposed in our panel – are
probably more suitable for this purpose.
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